Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System
Aims To identify HbA1c trajectories after the start of insulin treatment and to identify clinically applicable predictors of the response to insulin therapy. Methods The study population comprised 1203 people with Type 2 diabetes included in the Hoorn Diabetes Care System (n = 9849). Inclusion crite...
Gespeichert in:
| Veröffentlicht in: | Diabetic medicine 2016-06, Vol.33 (6), p.794-802 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 802 |
|---|---|
| container_issue | 6 |
| container_start_page | 794 |
| container_title | Diabetic medicine |
| container_volume | 33 |
| creator | Mast, M. R. Walraven, I. Hoekstra, T. Jansen, A. P. D. van der Heijden, A. A. W. A. Elders, P. J. M. Heine, R. J. Dekker, J. M. Nijpels, G. Hugtenburg, J. G. |
| description | Aims
To identify HbA1c trajectories after the start of insulin treatment and to identify clinically applicable predictors of the response to insulin therapy.
Methods
The study population comprised 1203 people with Type 2 diabetes included in the Hoorn Diabetes Care System (n = 9849). Inclusion criteria were: age ≥ 40 years; initiation of insulin during follow‐up after failure to reach HbA1c levels ≤ 53 mmol/mol (7%) with oral glucose‐lowering agents; and a follow up ≥ 2 years after initiating insulin. Latent class growth modelling was used to identify trajectories of HbA1c. Subjects considered to be ‘off target’ had HbA1c levels ≥ 53 mmol/mol (7.0%) during one‐third or more of the follow‐up time, and those considered to be ‘on target’ had HbA1c levels ≥ 53 mmol/mol (7.0%) during less than one‐third of the follow‐up time.
Results
Four HbA1c trajectories were identified. Most people (88.7%) were classified as having a stable HbA1c trajectory of ~57 mmol/mol (7.4%). Only 24.4% of the people were on target in response to insulin; this was associated with lower HbA1c levels and a higher age at the start of insulin treatment.
Conclusions
Using latent class growth modelling, four HbA1c trajectories were identified. A quarter of the people starting insulin were on target. Low HbA1c levels and advanced age at the start of insulin therapy were associated with better response to insulin therapy. Initiating insulin earlier improves the likelihood of achieving and sustaining glycaemic control.
What's new?
We showed the difficulties in reaching and sustaining a target HbA1c of ≤ 53 mmol/mol (7.0%) in the majority of people with Type 2 diabetes, even in a centrally organized managed diabetes care system.
Of the 1203 people initiating insulin therapy, 294 people (24.4%) were ‘on target’, whereas 909 people (75.6%) were ‘off target’ with an equal follow‐up of 5.5 years.
This study suggests that initiating insulin earlier increases the likelihood of achieving and sustaining glycaemic control. |
| doi_str_mv | 10.1111/dme.13110 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1790457488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1790457488</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4260-c72eace8e399e7d94f2b257624cc1bcc6d5c72c173727b47e6735fdbf277a9123</originalsourceid><addsrcrecordid>eNp10MtO3DAUBmCrKoKBsugLVJbY0EXAt8TjJZqZzrQaqFSgXVqOcyJMc8NOgLx93YZhgVRvLFvf-WX_CH2k5IzGdV7UcEY5peQdmlGRiSQVir5HMyIFSziR9AAdhnBPCGWKq310wDIVWUpmyKzKEmzvHqGBEHBbYteEoXIN7u_Am26MZ9xB21WAn1x_h2_GDjDDhTM59BDwJPGmbX2Dl7vbhfGAr8fQQ_0B7ZWmCnD8sh-h2y-rm8Um2X5ff11cbBMrWEYSKxkYC3PgSoEslChZzlKZMWEtza3NijQSSyWXTOZCQiZ5WhZ5yaQ0ijJ-hE6n3M63DwOEXtcuWKgq00A7BE2lIiKVYj6P9OQNvW8H38TXRTVXkrAsFVF9npT1bQgeSt15Vxs_akr039517F3_6z3aTy-JQ15D8Sp3RUdwPoEnV8H4_yS9vFztIpNpwsUWn18njP-t49dlqn9drfXPH5vt8hvf6jX_A-SRmkM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1789702654</pqid></control><display><type>article</type><title>Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Mast, M. R. ; Walraven, I. ; Hoekstra, T. ; Jansen, A. P. D. ; van der Heijden, A. A. W. A. ; Elders, P. J. M. ; Heine, R. J. ; Dekker, J. M. ; Nijpels, G. ; Hugtenburg, J. G.</creator><creatorcontrib>Mast, M. R. ; Walraven, I. ; Hoekstra, T. ; Jansen, A. P. D. ; van der Heijden, A. A. W. A. ; Elders, P. J. M. ; Heine, R. J. ; Dekker, J. M. ; Nijpels, G. ; Hugtenburg, J. G.</creatorcontrib><description>Aims
To identify HbA1c trajectories after the start of insulin treatment and to identify clinically applicable predictors of the response to insulin therapy.
Methods
The study population comprised 1203 people with Type 2 diabetes included in the Hoorn Diabetes Care System (n = 9849). Inclusion criteria were: age ≥ 40 years; initiation of insulin during follow‐up after failure to reach HbA1c levels ≤ 53 mmol/mol (7%) with oral glucose‐lowering agents; and a follow up ≥ 2 years after initiating insulin. Latent class growth modelling was used to identify trajectories of HbA1c. Subjects considered to be ‘off target’ had HbA1c levels ≥ 53 mmol/mol (7.0%) during one‐third or more of the follow‐up time, and those considered to be ‘on target’ had HbA1c levels ≥ 53 mmol/mol (7.0%) during less than one‐third of the follow‐up time.
Results
Four HbA1c trajectories were identified. Most people (88.7%) were classified as having a stable HbA1c trajectory of ~57 mmol/mol (7.4%). Only 24.4% of the people were on target in response to insulin; this was associated with lower HbA1c levels and a higher age at the start of insulin treatment.
Conclusions
Using latent class growth modelling, four HbA1c trajectories were identified. A quarter of the people starting insulin were on target. Low HbA1c levels and advanced age at the start of insulin therapy were associated with better response to insulin therapy. Initiating insulin earlier improves the likelihood of achieving and sustaining glycaemic control.
What's new?
We showed the difficulties in reaching and sustaining a target HbA1c of ≤ 53 mmol/mol (7.0%) in the majority of people with Type 2 diabetes, even in a centrally organized managed diabetes care system.
Of the 1203 people initiating insulin therapy, 294 people (24.4%) were ‘on target’, whereas 909 people (75.6%) were ‘off target’ with an equal follow‐up of 5.5 years.
This study suggests that initiating insulin earlier increases the likelihood of achieving and sustaining glycaemic control.</description><identifier>ISSN: 0742-3071</identifier><identifier>EISSN: 1464-5491</identifier><identifier>DOI: 10.1111/dme.13110</identifier><identifier>PMID: 26946450</identifier><identifier>CODEN: DIMEEV</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Blood Glucose - metabolism ; Cholesterol, HDL - metabolism ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Female ; Glycated Hemoglobin A - metabolism ; Humans ; Hyperglycemia ; Hypoglycemia ; Hypoglycemic Agents - therapeutic use ; Insulin ; Insulin - therapeutic use ; Male ; Middle Aged ; Netherlands ; Triglycerides - metabolism</subject><ispartof>Diabetic medicine, 2016-06, Vol.33 (6), p.794-802</ispartof><rights>2016 Diabetes UK</rights><rights>2016 Diabetes UK.</rights><rights>Diabetic Medicine © 2016 Diabetes UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4260-c72eace8e399e7d94f2b257624cc1bcc6d5c72c173727b47e6735fdbf277a9123</citedby><cites>FETCH-LOGICAL-c4260-c72eace8e399e7d94f2b257624cc1bcc6d5c72c173727b47e6735fdbf277a9123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdme.13110$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdme.13110$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26946450$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mast, M. R.</creatorcontrib><creatorcontrib>Walraven, I.</creatorcontrib><creatorcontrib>Hoekstra, T.</creatorcontrib><creatorcontrib>Jansen, A. P. D.</creatorcontrib><creatorcontrib>van der Heijden, A. A. W. A.</creatorcontrib><creatorcontrib>Elders, P. J. M.</creatorcontrib><creatorcontrib>Heine, R. J.</creatorcontrib><creatorcontrib>Dekker, J. M.</creatorcontrib><creatorcontrib>Nijpels, G.</creatorcontrib><creatorcontrib>Hugtenburg, J. G.</creatorcontrib><title>Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System</title><title>Diabetic medicine</title><addtitle>Diabet. Med</addtitle><description>Aims
To identify HbA1c trajectories after the start of insulin treatment and to identify clinically applicable predictors of the response to insulin therapy.
Methods
The study population comprised 1203 people with Type 2 diabetes included in the Hoorn Diabetes Care System (n = 9849). Inclusion criteria were: age ≥ 40 years; initiation of insulin during follow‐up after failure to reach HbA1c levels ≤ 53 mmol/mol (7%) with oral glucose‐lowering agents; and a follow up ≥ 2 years after initiating insulin. Latent class growth modelling was used to identify trajectories of HbA1c. Subjects considered to be ‘off target’ had HbA1c levels ≥ 53 mmol/mol (7.0%) during one‐third or more of the follow‐up time, and those considered to be ‘on target’ had HbA1c levels ≥ 53 mmol/mol (7.0%) during less than one‐third of the follow‐up time.
Results
Four HbA1c trajectories were identified. Most people (88.7%) were classified as having a stable HbA1c trajectory of ~57 mmol/mol (7.4%). Only 24.4% of the people were on target in response to insulin; this was associated with lower HbA1c levels and a higher age at the start of insulin treatment.
Conclusions
Using latent class growth modelling, four HbA1c trajectories were identified. A quarter of the people starting insulin were on target. Low HbA1c levels and advanced age at the start of insulin therapy were associated with better response to insulin therapy. Initiating insulin earlier improves the likelihood of achieving and sustaining glycaemic control.
What's new?
We showed the difficulties in reaching and sustaining a target HbA1c of ≤ 53 mmol/mol (7.0%) in the majority of people with Type 2 diabetes, even in a centrally organized managed diabetes care system.
Of the 1203 people initiating insulin therapy, 294 people (24.4%) were ‘on target’, whereas 909 people (75.6%) were ‘off target’ with an equal follow‐up of 5.5 years.
This study suggests that initiating insulin earlier increases the likelihood of achieving and sustaining glycaemic control.</description><subject>Adult</subject><subject>Aged</subject><subject>Blood Glucose - metabolism</subject><subject>Cholesterol, HDL - metabolism</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Female</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hypoglycemia</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Insulin - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Netherlands</subject><subject>Triglycerides - metabolism</subject><issn>0742-3071</issn><issn>1464-5491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10MtO3DAUBmCrKoKBsugLVJbY0EXAt8TjJZqZzrQaqFSgXVqOcyJMc8NOgLx93YZhgVRvLFvf-WX_CH2k5IzGdV7UcEY5peQdmlGRiSQVir5HMyIFSziR9AAdhnBPCGWKq310wDIVWUpmyKzKEmzvHqGBEHBbYteEoXIN7u_Am26MZ9xB21WAn1x_h2_GDjDDhTM59BDwJPGmbX2Dl7vbhfGAr8fQQ_0B7ZWmCnD8sh-h2y-rm8Um2X5ff11cbBMrWEYSKxkYC3PgSoEslChZzlKZMWEtza3NijQSSyWXTOZCQiZ5WhZ5yaQ0ijJ-hE6n3M63DwOEXtcuWKgq00A7BE2lIiKVYj6P9OQNvW8H38TXRTVXkrAsFVF9npT1bQgeSt15Vxs_akr039517F3_6z3aTy-JQ15D8Sp3RUdwPoEnV8H4_yS9vFztIpNpwsUWn18njP-t49dlqn9drfXPH5vt8hvf6jX_A-SRmkM</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Mast, M. R.</creator><creator>Walraven, I.</creator><creator>Hoekstra, T.</creator><creator>Jansen, A. P. D.</creator><creator>van der Heijden, A. A. W. A.</creator><creator>Elders, P. J. M.</creator><creator>Heine, R. J.</creator><creator>Dekker, J. M.</creator><creator>Nijpels, G.</creator><creator>Hugtenburg, J. G.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201606</creationdate><title>Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System</title><author>Mast, M. R. ; Walraven, I. ; Hoekstra, T. ; Jansen, A. P. D. ; van der Heijden, A. A. W. A. ; Elders, P. J. M. ; Heine, R. J. ; Dekker, J. M. ; Nijpels, G. ; Hugtenburg, J. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4260-c72eace8e399e7d94f2b257624cc1bcc6d5c72c173727b47e6735fdbf277a9123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Blood Glucose - metabolism</topic><topic>Cholesterol, HDL - metabolism</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Female</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hypoglycemia</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Insulin - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Netherlands</topic><topic>Triglycerides - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mast, M. R.</creatorcontrib><creatorcontrib>Walraven, I.</creatorcontrib><creatorcontrib>Hoekstra, T.</creatorcontrib><creatorcontrib>Jansen, A. P. D.</creatorcontrib><creatorcontrib>van der Heijden, A. A. W. A.</creatorcontrib><creatorcontrib>Elders, P. J. M.</creatorcontrib><creatorcontrib>Heine, R. J.</creatorcontrib><creatorcontrib>Dekker, J. M.</creatorcontrib><creatorcontrib>Nijpels, G.</creatorcontrib><creatorcontrib>Hugtenburg, J. G.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mast, M. R.</au><au>Walraven, I.</au><au>Hoekstra, T.</au><au>Jansen, A. P. D.</au><au>van der Heijden, A. A. W. A.</au><au>Elders, P. J. M.</au><au>Heine, R. J.</au><au>Dekker, J. M.</au><au>Nijpels, G.</au><au>Hugtenburg, J. G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System</atitle><jtitle>Diabetic medicine</jtitle><addtitle>Diabet. Med</addtitle><date>2016-06</date><risdate>2016</risdate><volume>33</volume><issue>6</issue><spage>794</spage><epage>802</epage><pages>794-802</pages><issn>0742-3071</issn><eissn>1464-5491</eissn><coden>DIMEEV</coden><abstract>Aims
To identify HbA1c trajectories after the start of insulin treatment and to identify clinically applicable predictors of the response to insulin therapy.
Methods
The study population comprised 1203 people with Type 2 diabetes included in the Hoorn Diabetes Care System (n = 9849). Inclusion criteria were: age ≥ 40 years; initiation of insulin during follow‐up after failure to reach HbA1c levels ≤ 53 mmol/mol (7%) with oral glucose‐lowering agents; and a follow up ≥ 2 years after initiating insulin. Latent class growth modelling was used to identify trajectories of HbA1c. Subjects considered to be ‘off target’ had HbA1c levels ≥ 53 mmol/mol (7.0%) during one‐third or more of the follow‐up time, and those considered to be ‘on target’ had HbA1c levels ≥ 53 mmol/mol (7.0%) during less than one‐third of the follow‐up time.
Results
Four HbA1c trajectories were identified. Most people (88.7%) were classified as having a stable HbA1c trajectory of ~57 mmol/mol (7.4%). Only 24.4% of the people were on target in response to insulin; this was associated with lower HbA1c levels and a higher age at the start of insulin treatment.
Conclusions
Using latent class growth modelling, four HbA1c trajectories were identified. A quarter of the people starting insulin were on target. Low HbA1c levels and advanced age at the start of insulin therapy were associated with better response to insulin therapy. Initiating insulin earlier improves the likelihood of achieving and sustaining glycaemic control.
What's new?
We showed the difficulties in reaching and sustaining a target HbA1c of ≤ 53 mmol/mol (7.0%) in the majority of people with Type 2 diabetes, even in a centrally organized managed diabetes care system.
Of the 1203 people initiating insulin therapy, 294 people (24.4%) were ‘on target’, whereas 909 people (75.6%) were ‘off target’ with an equal follow‐up of 5.5 years.
This study suggests that initiating insulin earlier increases the likelihood of achieving and sustaining glycaemic control.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>26946450</pmid><doi>10.1111/dme.13110</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0742-3071 |
| ispartof | Diabetic medicine, 2016-06, Vol.33 (6), p.794-802 |
| issn | 0742-3071 1464-5491 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1790457488 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Blood Glucose - metabolism Cholesterol, HDL - metabolism Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Female Glycated Hemoglobin A - metabolism Humans Hyperglycemia Hypoglycemia Hypoglycemic Agents - therapeutic use Insulin Insulin - therapeutic use Male Middle Aged Netherlands Triglycerides - metabolism |
| title | Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T07%3A02%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20insulin%20therapy%20in%20people%20with%20Type%202%20diabetes%20in%20the%20Hoorn%20Diabetes%20Care%20System&rft.jtitle=Diabetic%20medicine&rft.au=Mast,%20M.%20R.&rft.date=2016-06&rft.volume=33&rft.issue=6&rft.spage=794&rft.epage=802&rft.pages=794-802&rft.issn=0742-3071&rft.eissn=1464-5491&rft.coden=DIMEEV&rft_id=info:doi/10.1111/dme.13110&rft_dat=%3Cproquest_cross%3E1790457488%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1789702654&rft_id=info:pmid/26946450&rfr_iscdi=true |